Other

Hoffmann-la Roche Inc.

Curis, Inc.

Basf Aktiengesellschaft

Boehringer Mannheim Gmbh

F. Hoffmann-la Roche Ag

Spindelfabrik Suessen Schurr Stahlecker & Grill Gmbh

Spindelfabrik Sussen, Schurr, Stahlecker & Grill Gmbh

Bundesrepublik Deutschland Vertreten Durch Den Bundesminister Fur Gesundheit

Kurt Lang

Andreas Schaubmar

Fritz Stahlecker

Joerg Thomas Regula

Stephan Fischer

Tilman Schlothauer

Friederike Hesse

Petra Rueger

Hendrik Knoetgen

Christian Schantz

Friedrich Metzger

Tilman Seytter

Angelika Esswein

Walter Huber

Bernd Bohrmann

Manfred Brockhaus

Hans Koll

Michael Baier

Reinhard Kurth

Albrecht Werner

Hansruedi Loetscher

Ulrike Leser

Karl Weyer

Norbert Bannert

Diana Schuhbauer

Hans-Joachim Schoenfeld

Konrad Honold

Klaus-Peter Kuenkele

Lothar Kling

Friedbert Schmid

Martin Lanzendoerfer

Norbert Barauke

Apollon Papadimitriou

Karin Metzner

Achim Goepferich

Andreas Kreimeyer

Stefan Foser

Roland Gorlich

Rolf Erhardt

Beat Amrein

Tilmann Seytter

Karin Kellner

Ulrike Leser-Reiff

Michaela Schultz

Torsten Blunk

Jörg Regula

Hans Joachim Schoenfeld

Julia Schleypen

A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (V). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the &#x3b2;-A4 peptide/A&#x3b2;4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (V). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided. The antibody isoforms may for example be used in the pharmaceutical intervention of amyloidogenesis or amyloid-plaque formation and/or in the diagnosis of the same.

Antibodies against amyloid beta 4 with glycosylation in the variable region

Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

Method for the production of insulin-like growth factor-1

The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.

Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

A hedgehog conjugate which is characterized in that it contains: a) a polypeptide composed of 10 to 30 hydrophobic amino acids and/or amino acids which form transmembrane helices and are positively charged, b) 1 to 4 aliphatic, saturated or unsaturated hydrocarbon residues with a chain length of 10 to 24 C atoms and with a hydrophobic action or c) a hydrophobic thio compound covalently bound to a hedgehog protein and which has a several-fold increased activity and is suitable as a pharmaceutical agent.

Active hedgehog protein conjugate

The present invention makes available an optimal concentration of a hedgehog polypeptide for modulating growth and/or cartilage production by chondrocytes. The present invention allows for improvements in the culturing of chondrocytes to develop cartilaginous tissue ex vivo suitable for implantation to replace damaged or deteriorated cartilage in a patient.

Methods and reagents for tissue engineering of cartilage in vitro

The present invention provides isolated highly active hedgehog proteins esterified with a fatty acid having from 14 to 20 carbon atoms at the N-terminal domain of the protein. The highly active hh proteins are particularly useful therapeutic agents for treating bone disorders and neurodegenerative diseases. Methods for obtaining the highly active modified hedgehog proteins are also provided.

Active modified hedgehog proteins

A nucleic acid which can be used to express a polypeptide with interleukin-16 activity in a prokaryotic or eukaryotic host cell wherein the nucleic acid codes for a polypeptide with the amino acid sequence SEQ ID NO:2 or a SEQ ID NO:2 elongated N-terminally by an aspartic acid residue or a form shortened at the C-terminus by up to 8 amino acids, and is suitable for the production of an active IL-16 polypeptide.

Processed polypeptides with IL-16 activity, process for preparing the same and their use

Downstream of a drafting unit of a spinning machine, a condensing zone is provided, in which a drafted fiber strand still in an untwisted state is condensed by bundling. The condensing zone comprises a stationary suction slit, over which the fiber strand to be condensed is transported by an air-permeable transporting element. The suction slit defines the direction of a suction air stream by a guiding edge, which extends diagonally to the direction of motion of the transport element. The air stream positions the fibers of the fiber strand diagonally to the direction of motion of the transport element and so condenses the fiber strand. The suction slit begins with a starting width, which seizes the fiber strand to be condensed in its entire width. Directly downstream thereof the suction slit graduates in the form of a delta into a narrower effective width. The guiding edge continues an edge of the delta without deformation.

Arrangement for condensing a fiber strand

The present invention relates to a fine-toothed combing structure of an opening roller for an open-end spining machine. The teeth of the fine-toothed combing structure have a spacing which measures at least three times the height of the teeth. The front angle should not measure more than 10&deg;. This fine-toothed combing structure is preferably used for synthetic fibers.

Fine-toothed combing structure of an opening roller for an open-end spinning machine

A yarn withdrawal nozzle for an open-end rotor spinning apparatus comprises a short, funnel-shaped yarn deflecting surface, which begins at a plane front surface and graduates into a yarn withdrawal channel. The radius of curvature of the yarn deflecting surface measures a maximum of 3 mm. The front surface is formed as a tangential surface to the yarn deflecting surface, The small radius of curvature facilitates in particular the spinning of polyester yarns at a high rotor speed.

Yarn withdrawal nozzle for an open-end rotor spinning apparatus

Growing community of inventors

Penzberg, Germany

Kurt Lang